Narrative review / 2018
Cycles of fasting-mimicking diets are feasible, safe, and may enhance cancer therapies while protecting normal tissues.
This review discusses the molecular mechanisms and clinical applications of fasting and fasting-mimicking diets (FMDs) in cancer. Fasting and FMDs generate environments that reduce cancer cells' ability to survive, enhance the effects of cancer therapies, increase normal cell resistance to chemotherapy, and promote normal tissue regeneration. While water-only fasting is difficult for patients to tolerate, both animal and clinical studies demonstrate that cycles of low-calorie FMDs are feasible and generally safe. Multiple ongoing clinical trials are currently evaluating the impact of fasting or FMDs on treatment-related adverse events and efficacy.
- Study type
- Narrative review
- Who was studied
- Cancer patients and animal models
- What was measured
- Treatment-emergent adverse events, therapy efficacy, and safety/feasibility of FMDs
THE PAPER
Fasting and cancer: molecular mechanisms and clinical application.
Nencioni A, Caffa I, Cortellino S, Longo VD. Nat Rev Cancer, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.